Journal: British Journal of Cancer

Article Title: A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer

doi: 10.1038/s41416-020-01055-5

Figure Lengend Snippet: Treatment exposure of patients in the safety data set.

Article Snippet: In particular, more patients in the belotecan group finished all six cycles than in the topotecan group (belotecan vs. topotecan: 53% vs. 35%; Chi-square test, p = 0.022).

Techniques:

Journal: British Journal of Cancer

Article Title: A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer

doi: 10.1038/s41416-020-01055-5

Figure Lengend Snippet: Maximum percentage changes in tumour size (sum of the longest diameters of target-lesions) from baseline, in topotecan ( a ) and belotecan ( b ) groups. Colours indicate best overall responses determined from the start of treatment until disease progression/recurrence. p values were obtained from Chi-square tests for comparisons of ORR and DCR between groups.

Article Snippet: In particular, more patients in the belotecan group finished all six cycles than in the topotecan group (belotecan vs. topotecan: 53% vs. 35%; Chi-square test, p = 0.022).

Techniques: Biomarker Discovery

Journal: British Journal of Cancer

Article Title: A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer

doi: 10.1038/s41416-020-01055-5

Figure Lengend Snippet: Kaplan–Meier curves showing a PFS and b OS for belotecan and topotecan groups. p values were obtained from log-rank tests for comparisons of PFS and OS between groups. Vertical dashed line indicates 1-year OS rate. ORR objective response rate, DCR disease control rate, PFS progression-free disease, OS overall survival.

Article Snippet: In particular, more patients in the belotecan group finished all six cycles than in the topotecan group (belotecan vs. topotecan: 53% vs. 35%; Chi-square test, p = 0.022).

Techniques: Control

Journal: British Journal of Cancer

Article Title: A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer

doi: 10.1038/s41416-020-01055-5

Figure Lengend Snippet: HR (95% CI) < 1 indicates significantly longer survival in the belotecan group than in the topotecan group. Dagger indicates that patients with symptomatic brain metastasis within 3 months prior to study entry were excluded from this study. HR hazard ratio, ECOG PS Eastern Cooperative Oncology Group performance status, LD limited-stage disease, ED extensive-stage disease, RDI relative dose intensity.

Article Snippet: In particular, more patients in the belotecan group finished all six cycles than in the topotecan group (belotecan vs. topotecan: 53% vs. 35%; Chi-square test, p = 0.022).

Techniques:

Journal: British Journal of Cancer

Article Title: A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer

doi: 10.1038/s41416-020-01055-5

Figure Lengend Snippet: Stepwise Cox regression analyses for prognostic factors.

Article Snippet: In particular, more patients in the belotecan group finished all six cycles than in the topotecan group (belotecan vs. topotecan: 53% vs. 35%; Chi-square test, p = 0.022).

Techniques:

Journal: British Journal of Cancer

Article Title: A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer

doi: 10.1038/s41416-020-01055-5

Figure Lengend Snippet: Adverse events in patients in the safety data set.

Article Snippet: In particular, more patients in the belotecan group finished all six cycles than in the topotecan group (belotecan vs. topotecan: 53% vs. 35%; Chi-square test, p = 0.022).

Techniques:

Journal: Medicine

Article Title: Evidence-based evaluation of adjuvant therapy with Chinese medicine for cerebral small vessel disease: A systematic review and meta-analysis

doi: 10.1097/MD.0000000000036221

Figure Lengend Snippet: Characteristics of RCTls included in the meta-analysis.

Article Snippet: 4 , Zhang Zhanpeng, 2020 , 150 , 150 , 62.19 ± 6.08 , 62.17 ± 6.02 , 87/63 , 89/61 , Xifeng Tongyu Kaiqiao decoction + basic treatment , Basic treatment , 14 days , 1451213.

Techniques: Control

Journal: British Journal of Cancer

Article Title: A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer

doi: 10.1038/s41416-020-01055-5

Figure Lengend Snippet: Treatment exposure of patients in the safety data set.

Article Snippet: The DCR was significantly higher in the belotecan group compared to the topotecan group (belotecan vs. topotecan: 85% vs. 70%; Chi-square test , p = 0.030).

Techniques:

Journal: British Journal of Cancer

Article Title: A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer

doi: 10.1038/s41416-020-01055-5

Figure Lengend Snippet: Maximum percentage changes in tumour size (sum of the longest diameters of target-lesions) from baseline, in topotecan ( a ) and belotecan ( b ) groups. Colours indicate best overall responses determined from the start of treatment until disease progression/recurrence. p values were obtained from Chi-square tests for comparisons of ORR and DCR between groups.

Article Snippet: The DCR was significantly higher in the belotecan group compared to the topotecan group (belotecan vs. topotecan: 85% vs. 70%; Chi-square test , p = 0.030).

Techniques: Biomarker Discovery

Journal: British Journal of Cancer

Article Title: A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer

doi: 10.1038/s41416-020-01055-5

Figure Lengend Snippet: Kaplan–Meier curves showing a PFS and b OS for belotecan and topotecan groups. p values were obtained from log-rank tests for comparisons of PFS and OS between groups. Vertical dashed line indicates 1-year OS rate. ORR objective response rate, DCR disease control rate, PFS progression-free disease, OS overall survival.

Article Snippet: The DCR was significantly higher in the belotecan group compared to the topotecan group (belotecan vs. topotecan: 85% vs. 70%; Chi-square test , p = 0.030).

Techniques: Control

Journal: British Journal of Cancer

Article Title: A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer

doi: 10.1038/s41416-020-01055-5

Figure Lengend Snippet: HR (95% CI) < 1 indicates significantly longer survival in the belotecan group than in the topotecan group. Dagger indicates that patients with symptomatic brain metastasis within 3 months prior to study entry were excluded from this study. HR hazard ratio, ECOG PS Eastern Cooperative Oncology Group performance status, LD limited-stage disease, ED extensive-stage disease, RDI relative dose intensity.

Article Snippet: The DCR was significantly higher in the belotecan group compared to the topotecan group (belotecan vs. topotecan: 85% vs. 70%; Chi-square test , p = 0.030).

Techniques:

Journal: British Journal of Cancer

Article Title: A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer

doi: 10.1038/s41416-020-01055-5

Figure Lengend Snippet: Stepwise Cox regression analyses for prognostic factors.

Article Snippet: The DCR was significantly higher in the belotecan group compared to the topotecan group (belotecan vs. topotecan: 85% vs. 70%; Chi-square test , p = 0.030).

Techniques:

Journal: British Journal of Cancer

Article Title: A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer

doi: 10.1038/s41416-020-01055-5

Figure Lengend Snippet: Adverse events in patients in the safety data set.

Article Snippet: The DCR was significantly higher in the belotecan group compared to the topotecan group (belotecan vs. topotecan: 85% vs. 70%; Chi-square test , p = 0.030).

Techniques: